Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Run time: 42mins. What happens when clinical research is redesigned around the needs, preferences, and lives of real people? In this episode of The Future Prescription: Inside the Trends, discover how sponsors and CROs are aligning clinical and commercial priorities to create smarter, more inclusive, and scalable studies.
Excess aldosterone of > 15ng/dL, in the presence of low renin, is linked to hypertension (HTN) and chronic kidney disease (CKD)
As clinical trials evolve, one thing is certain: representativeness is no longer a nice-to-have; it’s a non-negotiable. The data are clear. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, 84% reported ramping up efforts to improve representativeness and accessibility in clinical research over the past few years.
Reflecting on the discussions from this year’s International Society for Pharmacoepidemiology (ISPE) Annual Meeting and looking ahead to the future of the field, I’m struck by the steady but significant evolution pharmacoepidemiology is undergoing driven in large part by innovations in real-world data (RWD).
Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases.
To characterize the use of and factors associated with GLP-1 initiation among US adults undergoing bariatric surgery.
Sanofi UK, a leading pharmaceutical company, sought an innovative solution to address challenges in clinical trial recruitment and feasibility.
There has been a proliferation of large-scale electronic health record (EHR) data platforms that pool across multiple healthcare organizations
Discover how partnering with TriNetX will enable you to advance rare disease research.
In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.
Pediatric obstructive sleep apnea (OSA) affects an estimated 1–3 % of children, corresponding to over 40 million cases globally.
Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.
Upcoming Webinar
From Data to Evidence: A Framework for RWD Study Design & Causal Inference
Thursday, July 16 | 11am ET
Generating credible evidence from real-world data (RWD) requires more than access to data — it demands intentional alignment between the research question, study design, and data source. Yet even experienced teams fall into the trap of starting with the data and working backward, a shortcut that can undermine the trustworthiness of study findings.
Join TriNetX Chief Scientific Officer Jeffrey Brown, PhD, and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab at Harvard, as they walk through a practical framework for designing rigorous RWD studies for causal inference. Attendees will leave with concrete tools for sequencing their research approach, evaluating data fitness, and applying sound decision-making to their own studies.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
